Business context and reporting period
Filing identity: The supplied filing is Cyclacel Pharmaceuticals, Inc.’s Form 10-K for the fiscal year ended December 31, 2021, not Bio Green Med Solution, Inc. It reports annual results, rather than a standalone 2021 fourth quarter.
Cyclacel is a clinical-stage biopharmaceutical company developing cancer drug candidates. Its main programs are fadraciclib, a CDK2/9 inhibitor, and CYC140, a PLK1 inhibitor; sapacitabine is also in development. The company had no product revenue in either 2021 or 2020.
Financial and operating highlights
| Metric | 2021 | 2020 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $15.5 million | $4.8 million |
| General and administrative expense | $7.5 million | $5.9 million |
| Operating loss | $22.9 million | $10.6 million |
| Net loss | $18.9 million | $8.4 million |
| Net cash used in operating activities | $18.5 million | $7.9 million |
| Cash and cash equivalents at year-end | $36.6 million | $33.4 million |
| Working capital at year-end | $35.6 million | $33.0 million |
Net loss attributable to common shareholders was $19.1 million in 2021, or $2.14 per share, compared with $12.4 million, or $3.42 per share, in 2020. The 2020 figure included a $3.8 million deemed dividend from the Series B preferred stock’s beneficial conversion feature; weighted-average common shares rose from 3.6 million to 8.9 million.
Research and development spending increased 225%, primarily as fadraciclib and CYC140 clinical, supply-manufacturing and preclinical work expanded. Other income fell to $0.2 million from $1.0 million, mainly due to lower royalties under a legacy asset purchase agreement. UK R&D tax-credit benefit increased to $3.8 million from $1.2 million. No operating margin is meaningful because the company had no revenue.
Financing activities provided $21.7 million in 2021, including approximately $13.5 million from a common-stock offering, $4.5 million from warrant exercises and $4.0 million from an at-the-market offering, partly offset by preferred dividends. The company had no material conventional debt disclosed; it reported lease liabilities and other operating liabilities. Year-end current liabilities were $5.3 million, total liabilities $5.3 million, and total assets $42.6 million.
Material changes, outlook and risks
- Management expected year-end 2021 cash, together with anticipated operating cash flows including R&D tax credits, to fund planned operations through mid-2023. It stated that the company did not have enough funds to complete development and commercialization of any candidate and would need additional capital beyond that runway.
- Management expected R&D expense to increase in 2022 as streamlined Phase 1/2 programs advanced, and G&A expense to decrease due to lower recruitment and professional costs. It anticipated higher R&D tax credits in 2022, dependent on eligible spending and applicable rules.
- Fadraciclib oral Phase 1/2 studies were underway in solid tumors and hematologic cancers; CYC140 oral solid-tumor development was underway, with a hematologic study planned. Sapacitabine’s Phase 3 SEAMLESS study in elderly AML patients failed its primary overall-survival endpoint; a separate sapacitabine/olaparib investigator-sponsored study was being closed for low enrollment.
- Principal risks include clinical-trial failure or delay, unvalidated biomarkers, reliance on CROs and third-party manufacturers, regulatory uncertainty, competition, and inability to raise capital on acceptable terms. COVID-19 had affected trial operations and enrollment. The company also cited potential supply-chain effects from geopolitical tensions.
- The company reported no material legal proceedings at December 31, 2021. Management concluded internal control over financial reporting was effective; the auditor did not provide an ICFR effectiveness opinion because the company was a smaller reporting company. The audited financial statements received an unqualified opinion; clinical-trial accrual estimation was identified as a critical audit matter.
Important facts for investors to verify
- Confirm the issuer: this filing is for Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC, CYCCP), not the company named in the request metadata.
- Check subsequent cash use, financing, and the current runway; the mid-2023 estimate was management’s forecast as of the filing, not a guarantee.
- Review updated clinical results, enrollment, safety, and milestones for fadraciclib and CYC140, and any regulatory path for sapacitabine after SEAMLESS.
- Assess dilution and potential share supply from equity offerings, warrants, options, convertible preferred shares, and the $50 million ATM facility; 9,993,135 common shares were reported outstanding as of March 24, 2022.
- Review the $2.3 million accrued R&D balance and assumptions underlying clinical-trial accruals, as well as the availability and rules governing UK R&D tax credits.